Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
Recruiting · NCT07630402 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Rochester
View the official record on ClinicalTrials.gov →Interventions studied
Echocardiogram
What this trial is about
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).
Who can take part
Age range
18 Years to 79 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Female sex, age 18-79 years.
- Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
- Baseline LVEF ≥ 55 % by 2-D echocardiography.
- Ability to provide informed consent.
Exclusion criteria
- Prior HF, myocardial infarction, or cardiomyopathy.
- Atrial fibrillation or significant valvular heart disease.
- Cumulative anthracycline dose ≥ 250 mg/m².
- Pregnancy or lactation.
- Inability to comply with study procedures.
Where it is running
1 location listed across 1 US state.
- Wilmot Cancer Center - Rochester, New York, United States